![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Novartis Pharmaceuticals |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00805675 |
The purpose of this study is to compare the safety, tolerability and effectiveness of 12 weeks of treatment with telbivudine 600 mg daily plus tenofovir DF 300 mg one daily (OD) taken together vs tenofovir DF 300 mg once daily (QD) or vs telbivudine 600 mg monotherapy daily (QD). This is an open labeled, active controlled, viral kinetics study which means the subjects and study doctor will know what study drug subjects have been assigned. This study is open to male and female subjects, <40 years of age, who have been infected with HBV for at least 6 months and have not received oral treatment for HBV.
Condition | Intervention | Phase |
---|---|---|
Hepatitis B Virus |
Drug: Telbivudine Drug: Tenofovir Drug: Telbivudine plus tenofovir |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Parallel Assignment |
Official Title: | A Randomized, Open-Label, Controlled, Exploratory Trial to Characterize the Results of Daily Oral Administration of Telbivudine 600 mg and Tenofovir Disproxil Fumarate 300 mg in Combination or Telbivudine 600 mg or Tenofovir Disproxil Fumarate 300 mg Monotherapy Given Over 12 Weeks on the Kinetics of Hepatitis B Virus DNA in Adults With HBeAg Positive Compensated CHB |
Estimated Enrollment: | 60 |
Study Start Date: | November 2008 |
Estimated Primary Completion Date: | August 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Telbivudine 600 mg monotherapy: Experimental | Drug: Telbivudine |
Tenofovir disproxil fumarate 300 mg monotherapy: Active Comparator | Drug: Tenofovir |
Telbivudine 600 mg and Tenofovir 300 mg: Active Comparator | Drug: Telbivudine plus tenofovir |
Ages Eligible for Study: | 18 Years to 40 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
China | |
Department of Medicine, Queen Mary Hospital | Recruiting |
Hong Kong, China | |
Contact: George Lau, MD +852-2855 3578 gkklau@netvigator.com |
Study Director: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
Responsible Party: | Novartis Pharmaceuticals ( External Affairs ) |
Study ID Numbers: | CLDT600AHK01 |
Study First Received: | December 9, 2008 |
Last Updated: | January 9, 2009 |
ClinicalTrials.gov Identifier: | NCT00805675 History of Changes |
Health Authority: | Hong Kong: Department of Health |
Chronic HBV Asian adult subjects with chronic HBV, in immune tolerant phase, and positive for hepatitis B e antigen (HBeAg) |
Liver Diseases Anti-HIV Agents Hepatitis, Viral, Human Antiviral Agents Reverse Transcriptase Inhibitors Hepatitis Virus Diseases |
Digestive System Diseases Anti-Retroviral Agents Hepatitis B Tenofovir DNA Virus Infections Tenofovir disoproxil |
Anti-Infective Agents Liver Diseases Anti-HIV Agents Molecular Mechanisms of Pharmacological Action Hepatitis, Viral, Human Enzyme Inhibitors Antiviral Agents Hepadnaviridae Infections Pharmacologic Actions Reverse Transcriptase Inhibitors |
Hepatitis Virus Diseases Digestive System Diseases Anti-Retroviral Agents Therapeutic Uses Hepatitis B Tenofovir DNA Virus Infections Nucleic Acid Synthesis Inhibitors Tenofovir disoproxil |